# SABS catalysts: SAB Biotherapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sabs/catalysts

> SAB Biotherapeutics, Inc. (SABS) has 4 upcoming catalysts. The next is the SAB Biotherapeutics, Inc. topline data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SABS?

SAB Biotherapeutics, Inc. (SABS) has 4 upcoming catalysts. The next is the SAB Biotherapeutics, Inc. topline data readout, 2H 2027. SEC Form 10-K: "Global trial startup activities are underway and study is actively enrolling and dosing patients at multiple global sites with topline data expected in the second half of 2027." [Calendar and source filings](https://sec-api.dev/companies/sabs/catalysts)

Source: SEC Form 10-K, accession 0001833214-26-000003, https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/sabs-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-03-09. Cite: https://sec-api.dev/companies/sabs/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | SAB Biotherapeutics, Inc. |
| Ticker | SABS (Nasdaq) |
| SEC CIK | 1833214 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/sabs |

## Cash runway

Cash $205.3M as of 2026-09-30; quarterly burn $13.0M; about 47.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-448600).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2024 | [SAB Biotherapeutics, Inc. topline data readout](https://sec-api.dev/companies/sabs/catalysts) | SABS |  | completed, positive | "We received an Investigational New Drug (IND) clearance from the FDA in May 2024 and announced positive topline data from our Phase 1 clinical trial of SAB-142 in January 2025 and December 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1833214/000119312526448600/sabs-20260930.htm)) |
| January 28, 2025 | [SAB Biotherapeutics, Inc. topline data readout](https://sec-api.dev/companies/sabs/catalysts) | SABS |  | completed, positive | "MIAMI, January 28, 2025 - SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833214/000095017025009474/sabs-ex99_1.htm)) |
| mid-2026 | [SAB Biotherapeutics, Inc. interim data readout](https://sec-api.dev/companies/sabs/catalysts) | SABS |  | scheduled | "This Phase 2b study is expected to initiate in the middle of 2025 with interim data in the middle of 2026 and topline data in 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1833214/000095017025046994/sabs-20241231.htm)) |
| 2H 2027 | [SAB Biotherapeutics, Inc. topline data readout](https://sec-api.dev/companies/sabs/catalysts) | SABS |  | scheduled | "Global trial startup activities are underway and study is actively enrolling and dosing patients at multiple global sites with topline data expected in the second half of 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/sabs-20251231.htm)) |
| 2H 2027 | [SAB Biotherapeutics, Inc. topline data readout](https://sec-api.dev/companies/sabs/catalysts) | SABS |  | scheduled | "SAB-142 is currently being evaluated in the registrational Phase 2b SAFEGUARD study in people within 100 days of a Stage 3 T1D diagnosis, with enrollment expected to be completed in Q4 2026 and topline data anticipated in 2H 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833214/000119312526419769/sabs-ex99_1.htm)) |
| November 2027 | [High dose sab-142 primary completion](https://sec-api.dev/pdufa/high-dose-sab-142) | SABS | Type 1 Diabetes | scheduled | "NCT07187531 (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor SAb Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07187531)) |
| Nov 2027 to Feb 2028 | [High dose sab-142 topline data readout](https://sec-api.dev/pdufa/high-dose-sab-142) | SABS | Type 1 Diabetes | scheduled | "NCT07187531 (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor SAb Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07187531)) |

## Drugs

- [High dose sab-142](https://sec-api.dev/pdufa/high-dose-sab-142): Type 1 Diabetes

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sabs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SABS catalysts: SAB Biotherapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sabs/catalysts

```bibtex
@misc{secapidev_companies_sabs_catalysts_20261116,
  title        = {SABS catalysts: SAB Biotherapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sabs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sabs_catalysts_20261116","title":"SABS catalysts: SAB Biotherapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sabs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
